

## DAFTAR PUSTAKA

- Akakpo, P. *et al.* (2015) 'Ovarian Cancer in Ghana, a 10 Year Histopathological Review of Cases at Korle Bu Teaching Hospital', *African Journal of Reproductive Health*, 19(4), pp. 102–106.
- Atallah, G. A. *et al.* (2021) 'New predictive biomarkers for ovarian cancer', *Diagnostics*, 11(3). doi: 10.3390/diagnostics11030465.
- Bakacak, M. *et al.* (2016) 'Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses', *Journal of the Turkish German Gynecology Association*, 17(1), pp. 21–25. doi: 10.5152/jtgga.2015.0152.
- Balkwill, F. and Mantovani, A. (2001) 'Inflammation and cancer: Back to Virchow?', *Lancet*, 357(9255), pp. 539–45. doi: 10.1016/S0140-6736(00)04046-0.
- Barbolina, M. V. (2018) 'Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma', *Cancers*, 10(11), pp. 1–18. doi: 10.3390/cancers10110444.
- Bindal, J. and Bankey, S. (2017) 'Prevalence of ovarian tumours among ovarian mass lesions in Gajra Raja Medical College, Gwalior, India', *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, 6(9), p. 3907. doi: 10.18203/2320-1770.ijrcog20174032.
- Browning, L. *et al.* (2018) 'IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis', *Cancer Management and Research*, 10, pp. 6685–93. doi: 10.2147/CMAR.S179189.
- Cerne, K. and Kobal, B. (2018) 'Ascites in Advanced Ovarian Cancer', *Ovarian Cancer - From Pathogenesis to Treatment*. doi: 10.5772/intechopen.72698.
- Chaluvally-Raghavan, P. *et al.* (2016) 'Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian

- Cancer', *Cell Reports*, 15(7), pp. 1493–1504. doi: 10.1016/j.celrep.2016.04.034.
- Chang, L.-C. *et al.* (2018) 'Prognostic factors in epithelial ovarian cancer: A population-based study', *PLOS ONE*. Edited by A. Ahmad, 13(3), p. e0194993. doi: 10.1371/journal.pone.0194993.
- Charkhchi, P. *et al.* (2020) 'CA125 and Ovarian Cancer: A Comprehensive Review', *Shipping World and Shipbuilder*, 17, pp. 1–29. doi: 10.1190/1.9781560802662.ch1.
- Chen, Y. *et al.* (2015) 'Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer', *Asian Pacific Journal of Cancer Prevention*, 16(3), pp. 933–939. doi: 10.7314/APJCP.2015.16.3.933.
- Darai, E. *et al.* (2003) 'Serum and cyst fluid levels of interleukin (IL) 6, IL 8 and tumour necrosis factor alpha in women with endometriomas and benign and malignant cystic ovarian tumours', *Human Reproduction*, 18, pp. 1681–1685.
- Dinca, A. L. *et al.* (2020) 'Prognostic Factors in Advanced Ovarian Cancer - A Clinical Trial', *Chirurgia*, 115(1), p. 50. doi: 10.21614/chirurgia.115.1.50.
- Dochez, V. *et al.* (2019) 'Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review', *Journal of Ovarian Research*, 12(1), p. 28. doi: 10.1186/s13048-019-0503-7.
- Ezzati, M. *et al.* (2014) 'Recent advancements in prognostic factors of epithelial ovarian carcinoma', *ISRN Obstetrics and Gynecology*, 2014. doi: 10.1155/2014/953509.
- Feng, Y. *et al.* (2022) 'Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes', *Journal of Ovarian Research*, 15(1), pp. 1–12. doi: 10.1186/s13048-022-00994-2.
- Funston, G. *et al.* (2020) 'The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A

- population-based cohort study', *PLoS Medicine*, 17(10), pp. 1–18. doi: 10.1371/journal.pmed.1003295.
- Grigore, M. *et al.* (2021) 'Large ovarian tumors in adolescents, a systematic review of reported cases, diagnostic findings and surgical management', *Taiwanese Journal of Obstetrics and Gynecology*, 60(4), pp. 602–608. doi: 10.1016/j.tjog.2021.05.005.
- Hakim, A. A. *et al.* (2009) 'Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu', *Cancer Prevention Research*, 2(2), pp. 114–121. doi: 10.1158/1940-6207.CAPR-08-0065.
- Holschneider, C. H. and Berek, J. S. (2000) 'Ovarian Cancer : Epidemiology , Biology , and', pp. 3–10.
- Hufnagel, D. H. *et al.* (2020) 'Platelets, thrombocytosis, and ovarian cancer prognosis: Surveying the landscape of the literature', *International Journal of Molecular Sciences*, 21(21), pp. 1–18. doi: 10.3390/ijms21218169.
- Hunn, J. and Rodriguez, G. C. (2012) 'Ovarian cancer: Etiology, risk factors, and epidemiology', *Clinical Obstetrics and Gynecology*, 55(1), pp. 3–23. doi: 10.1097/GRF.0b013e31824b4611.
- Isobe, A. *et al.* (2015) 'Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer', *PLoS ONE*, 10(2), p. e0118080. doi: 10.1371/journal.pone.0118080.
- Javdekar, R. and Maitra, N. (2015) 'Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass', *Journal of Obstetrics and Gynecology of India*, 65(2), pp. 117–121. doi: 10.1007/s13224-014-0609-1.
- Kalu, E. *et al.* (2007) 'Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis', *Journal of Obstetrics and Gynaecology Research*, 33, pp. 490–495.
- Kampan, N. C. *et al.* (2020) 'Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer', *Scientific Reports*, 10(1), pp. 1–15. doi: 10.1038/s41598-020-59009-z.

- Kheiri, S. A. *et al.* (2018) 'Histopathological pattern and age distribution, of malignant ovarian tumor among sudanese ladies', *Open Access Macedonian Journal of Medical Sciences*, 6(2), pp. 237–241. doi: 10.3889/OAMJMS.2018.067.
- Kipps, E., Tan, D. S. P. and Kaye, S. B. (2013) 'Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Europe PMC Funders Author Manuscripts', *Nat Rev Cancer*, 13(4), pp. 273–282. doi: 10.1038/nrc3432.Meeting.
- Lertkhachonsuk, A. aroon *et al.* (2020) 'Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors', *Journal of Obstetrics and Gynaecology Research*, 46(11), pp. 2287–2291. doi: 10.1111/jog.14427.
- Lheureux, S. *et al.* (2019) 'Epithelial ovarian cancer', *The Lancet*, 393(10177), pp. 1240–1253. doi: 10.1016/S0140-6736(18)32552-2.
- Lippitz, B. E. and Harris, R. A. (2016) 'Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis', *Oncolmmunology*, p. e1093722. doi: 10.1080/2162402X.2015.1093722.
- Macciò, A. and Madeddu, C. (2012) 'Inflammation and ovarian cancer', *Cytokine*, 58(2), pp. 133–47. doi: 10.1016/j.cyto.2012.01.015.
- McDonald, J. *et al.* (2010) 'Predicting risk of malignancy in adnexal masses', *Obstet. Gynecol*, 115, pp. 687–94.
- Momenimovahed, Z. *et al.* (2019) 'Ovarian cancer in the world: Epidemiology and risk factors', *International Journal of Women's Health*, 11, pp. 287–299. doi: 10.2147/IJWH.S197604.
- Moolthiya, W. and Yuenyao, P. (2009) 'The Risk of Malignancy Index (RMI) in Diagnosis of Ovarian Malignancy', *Asian Pacific Journal of Cancer Prevention*, 10(5), pp. 865–868.
- Moore, R. G. *et al.* (2009) 'A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a

- pelvic mass', *Gynecologic Oncology*, 112(1), pp. 40–46. doi: 10.1016/j.ygyno.2008.08.031.
- NCCN Panel Members (2021) *Ovarian Cancer, NCCN Guidelines for Patients*.
- Rangaswamy, S., Rajkumar, G. C. and Sharada, P. (2020) 'Expression of proinflammatory cytokine INTERLEUKIN 6 in oral submucous fibrosis and oral squamous cell carcinoma : Immunohistochemical study', 07(11), pp. 5823–5832.
- Renjen, P. N. *et al.* (2008) 'Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature', *Ann Indian Acad Neurol*, 21(4), pp. 311–314.
- Rusda, M. *et al.* (2019) 'IHC Expression Relationships MMP7 and VEGF With Normal Ovaries and Ovarian Pathologies Muhammad', *Sumatera Medical Journal (SUMEJ)*, 02(01), pp. 85–95. Available at:  
<https://scholar.archive.org/work/qhduuy7vzbav7f42jtiu5oqlpy/access/wayback/https://talenta.usu.ac.id/smj/article/download/724/669>.
- Savant, S. S., Sriramkumar, S. and O'hagan, H. M. (2018) 'The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer', *Cancers*, 10(8), pp. 1–10. doi: 10.3390/cancers10080251.
- Sharadha, S. O. *et al.* (2015) 'Ovarian Masses: Changing Clinico Histopathological Trends', *Journal of Obstetrics and Gynecology of India*, 65(1), pp. 34–38. doi: 10.1007/s13224-014-0575-7.
- Smith, C. (2017) 'A Resident's Perspective of Ovarian Cancer', *Diagnostics*, 7(2), p. 24. doi: 10.3390/diagnostics7020024.
- Tewari, K. S. and Monk, B. J. (2015) *The 21st Century Handbook of Clinical Ovarian Cancer*. New York: Springer.
- Torre, L. A. *et al.* (2018) 'Ovarian cancer statistics, 2018', *CA: A Cancer Journal for Clinicians*, 68(4), pp. 284–296. doi: 10.3322/caac.21456.

- Utami, T. W. *et al.* (2015) 'Accuracy of Intraoperative Frozen Section in the Diagnosis of Ovarian Neoplasms', *Open Journal of Obstetrics and Gynecology*, 05(01), pp. 14–22. doi: 10.4236/ojog.2015.51003.
- Wertel, I. *et al.* (2020) 'Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+Inflammatory Cells with PD-L1+/PD-L2+Expression in Patients with Different Manifestation of Ovarian Cancer', *Journal of Immunology Research*. doi: 10.1155/2020/1715064.
- Whitwell, H. J. *et al.* (2020) 'Improved early detection of ovarian cancer using longitudinal multimarker models', *British Journal of Cancer*, 122(6), pp. 847–856. doi: 10.1038/s41416-019-0718-9.
- Yazdani, S. *et al.* (2018) 'The predictive role of preoperative leukocytosis, anemia and thrombocytosis with the severity of epithelial ovarian tumors', *Journal of Babol University of Medical Sciences*, 20(12), pp. 21–27.
- Yeung, T.-L., Leung, C. S. and Mok., S. C. (2015) 'Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis', *Am J Physiol Cell Physiol.*, 309(7), pp. C444–C456.
- Yildirim, M., Demir Cendek, B. and Filiz Avsar, A. (2015) 'Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios', *Molecular and Clinical Oncology*, 3(2), pp. 317–321. doi: 10.3892/mco.2014.481.
- Yousif, H. M. *et al.* (2019) 'Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA', *Journal of Taibah University Medical Sciences*, 14(1), pp. 73–78. doi: 10.1016/j.jtumed.2018.11.005.
- Zhang, B., Zhang, L. and Meng, G. (2021) 'Clinical analysis of 52 adolescent patients with ovarian masses  $\geq 10$  cm in diameter', *Journal of International Medical Research*, 49(8). doi: 10.1177/03000605211032781.

Zheng, H. *et al.* (2019) 'Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses', *Medicine (United States)*, 98(7), pp. 1–6. doi: 10.1097/MD.00000000000014577.

## LAMPIRAN 1

### NASKAH PENJELASAN UNTUK RESPONDEN

Selamat pagi, saya dr. Aida Uzaya yang akan melakukan penelitian tentang:

#### **Pemeriksaan Il-6 Sebagai Pertanda Keganasan Ovarium Tipe Epitel Prabedah**

Perlu ibu ketahui bahwa karsinoma ovarium merupakan kanker yang perlu mendapat perhatian khusus para perempuan, kanker ini sangat berbahaya dan sangat tinggi angka kematiannya. Karsinoma ovarium merupakan kanker penyebab kematian kelima pada perempuan di dunia barat sedangkan frekuensi relatifnya menempati urutan ke 3 dari 10 tumor primer pada perempuan di Indonesia. Pada stadium awal penyakit ini belum bergejala dan gejala akan muncul jika penyakit ini telah menyebar ke organ tubuh yang lain. Pengobatan kanker ovarium sampai saat ini belum memberikan hasil yang memuaskan. Oleh karena itu, saya akan melakukan pemeriksaan kadar Interleukin-6 (IL-6), suatu sitokin pro inflamasi yang berfungsi untuk meningkatkan proliferasi, invasi dan metastasis sel pada tumor ovarium. Melalui penelitian ini nantinya saya berharap akan memperoleh hasil yang bermanfaat untuk mendeteksi secara lebih dini kanker ovarium dan penanganan lebih lanjut.

Adapun prosedur yang akan saya lakukan adalah mengambil sampel darah ibu yang sama sekali tidak akan mengganggu dan mempengaruhi penatalaksanaan pengobatan yang akan diberikan kepada ibu selama dirawat di rumah sakit ini.

Saya sangat mengharapkan ibu bersedia untuk ikut dalam penelitian ini dan bila bersedia diharapkan dapat memberikan persetujuan tertulis. Keikutsertaan ibu dalam penelitian ini bersifat sukarela dan tanpa paksaan, oleh karena itu ibu berhak menolak atau mengundurkan diri tanpa risiko kehilangan hak untuk mendapatkan pelayanan kesehatan di rumah sakit ini dengan kata lain penolakan atau pengunduran diri ibu tidak akan mempengaruhi pelayanan kesehatan yang seharusnya ibu dapatkan.

Kalau ibu setuju untuk berpartisipasi, maka saya akan menanyakan beberapa hal, antara lain data pribadi ibu, riwayat penyakit, riwayat penyakit dalam keluarga, riwayat pekerjaan, riwayat pemakaian kontrasepsi dan lain-lain. Saya juga akan melakukan beberapa pemeriksaan antara lain pemeriksaan tanda vital dan keadaan umum ibu serta melakukan



pengambilan data hasil USG dan data laboratorium penunjang sesuai prosedur tatalaksana untuk penyakit ibu.

Pada saat ibu sebelum dioperasi atau dikemoterapi akan dilakukan pengambilan sampel darah dan akan diperiksa di Laboratorium Patologi Klinik FK UNHAS. Seluruh biaya penelitian akan menjadi tanggungan dokter peneliti dan tidak dibebankan pada ibu.

Bila ibu merasa masih ada yang perlu saya jelaskan atau belum dimengerti dengan baik, maka ibu berhak menanyakan dan akan saya jelaskan kepada ibu. Nama saya: dr. Aida Uzaya (telepon 081354295036/081233502544).

Data dalam penelitian ini akan dikumpulkan dan disimpan tanpa menyebutkan nama ibu dalam arsip tertulis atau elektronik (komputer), yang tidak bisa dilihat orang lain selain peneliti atau tim dari Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Hasanuddin.

Sekali lagi, jika ibu setuju untuk berpartisipasi, diharapkan menandatangani surat persetujuan mengikuti penelitian. Atas kesediaan dan kerjasamanya saya ucapkan banyak terima kasih.

#### **Identitas peneliti**

**Nama** : dr. Aida Uzaya  
**Alamat** : PPDS Obgin Fak. Kedokteran Unhas  
**Telepon** : 0813 5429 5036 / 0812 3350 2544

**DISETUJUI OLEH**  
**KOMISI ETIK PENELITIAN**  
**KESEHATAN FAK.**  
**KEDOKTERAN UNHAS**  
**Tgl 7 Maret 2022**

## LAMPIRAN 2

### FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN SETELAH MENDAPAT PENJELASAN

Saya yang bertanda tangan dibawah ini :

Nama : .....

Umur : .....

Alamat : .....

Pekerjaan : .....

No Telepon : .....

Dengan sesungguhnya saya menyatakan bahwa setelah mendapat penjelasan dan menyadari manfaat penelitian yang berjudul **“Pemeriksaan II-6 Sebagai Pertanda Keganasan Ovarium Tipe Epitel Prabedah”** maka saya setuju untuk diikutsertakan dalam penelitian ini dan bersedia berperan serta dengan mematuhi ketentuan yang berlaku dalam penelitian ini dan memberikan keterangan yang sebenarnya.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan sehingga saya bisa menolak ikut dan mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Juga saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti, demikian juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini, akan dibiayai oleh peneliti.

Demikian pernyataan ini saya buat dengan penuh kesadaran untuk dipergunakan sebagaimana mestinya.

	<b>NAMA</b>	<b>TANDA TANGAN</b>	<b>TGL/BLN/THN</b>
Klien	.....	.....	.....
Saksi 1	.....	.....	.....
Saksi 2	.....	.....	.....

**Penanggung Jawab Penelitian :**

Nama : dr. Aida Uzaya  
Alamat : PPDS Obgin Fak. Kedokteran UNHAS  
Telepon : 0813 5429 5036 / 0812 3350 2544

**Penanggung Jawab Medik:**

1. Nama : Prof. Dr. dr. Syahrul rauf, Sp.OG(K)  
Telepon : 0811 416 070
2. Nama : Dr. dr. Trika Irianta, Sp.OG(K)  
Telepon : 0812 422 5531

**DISETUJUI OLEH  
KOMISI ETIK PENELITIAN  
KESEHATAN FAK.  
KEDOKTERAN UNHAS  
Tgl 7 Maret 2022**

### LAMPIRAN 3. Dummy Tabel

Tabel 1 Distribusi frekuensi karakteristik pasien


Karakteristik	Frekuensi	Persentase (%)
Usia		
< 60 tahun		
≥ 60 tahun		
Paritas		
nullipara		
multipara		
Usia Menarche		
< 12 tahun		
≥ 12 tahun		
Keganasan		
Jinak		
Ganas		
Kadal IL-6		
< 3,75 pg/mL		
≥ 3,75 pg/mL		

Tabel 2. Hasil perbandingan cut off IL-6 dengan neoplasma ovarium

Cut off IL-6	Ganas		Jinak	
	n	%	n	%
< 3,75 pg/mL				
≥ 3,75 pg/mL				
Total				

## LAMPIRAN 4.

### REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN KESEHATAN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari, M.Med.PHD, Sp.GK. TELP. 081241850858, 0411 5790103, Fax : 0411-581431

#### REKOMENDASI PERSETUJUAN ETIK

Nomor : 104/UN4.6.4.5.31/PP36/2022

Tanggal: 7 Maret 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21120743	No Sponsor Protokol	
Peneliti Utama	<b>dr. Aida Uzaya</b>	Sponsor	
Judul Peneliti	Perbandingan Kadar IL-6 Prabedah Antara Neoplasma Ovarium Tipe Jinak Dan Tipe Ganas Epitelial		
No Versi Protokol	2	Tanggal Versi	7 Maret 2022
No Versi PSP	2	Tanggal Versi	7 Maret 2022
Tempat Penelitian	RS Universitas Hasanuddin, RS Dr. Wahidin Sudirohusodo, RS Ibnu Sina, RS Faisal dan RS Siti Khadija I Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 7 Maret 2022 sampai 7 Maret 2023	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWs	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWs	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

#### Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 5.

SURAT IZIN PENELITIAN



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN  
DEPARTEMEN OBSTETRI & GINEKOLOGI

Jl. P.Kemerdekaan Km. 11 RS Pendidikan Unhas Lt.3 Tamalanrea Makassar 90245  
Telp : (0411) 585859 Fax. 585688 E-mail : obgin.unhas@yahoo.co.id

No : 805/UN4.6.7/PT.01.04/2022  
Hal : Permohonan Ijin melakukan penelitian

Makassar, 10 Januari 2022

Yth. **Direktur RSPTN Universitas Hasanuddi**  
Makassar

Dengan hormat disampaikan bahwa salah satu Peserta Program Dokter Spesialis Departemen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Hasanuddin :

Nama : dr. Aida Uzaya  
Nim : C055181008

Bermaksud melakukan penelitian dengan judul :

***"UJI DIAGNOSTIK IL-6 SEBAGAI DIAGNOSTIK PRABEDAH KARSINOMA OVARIUM TIPE EPITELIAL"***

Sehubungan dengan maksud tersebut kami mohon kiranya dapat diberikan ijin kepada peserta PPDS untuk melakukan penelitian di RSPTN Universitas Hasanuddi Makassar.

Demikian permohonan kami, atas ijin dan kerjasamanya kami ucapkan terima kasih.



Ketua Departemen,

**Prof. Dr. dr. Syahrul Rauf, SpOG(K)**

Nip. 19621116 198903 1 003

**LAMPIRAN 6.**

**DATA PENELITIAN**

NO	NAMA	UMUR	PARITAS	USIA MENAR CHE	LEUKO SIT	HB	Trom bosit	IL 6	CURIGA GANAS	ASCITES	UKURAN TUMOR	CA-125	RMI
1	HAMIRA	50	P0A0	14	10.7	10.3	742	2.72	GANAS	TIDAK ADA	12X8X4	179.42	538.26
2	MIRA DAMA	28	NONA	12	2.3	12.3	183	6.79	GANAS	ADA	21,9X11,2,18,46	521.73	1565.19
3	RIFKA AULIA	17	NONA	14	11.1	14	403	3.06	JINAK	TIDAK ADA	12,5X10X4	15.40	15.40
4	WAODE IRMA NU AINI	23	NONA	14	6.7	12.6	360	2.43	GANAS	ADA	18X10,43X17,85	97.53	292.50
5	SURIANI	70	P6A0	15	14.1	10.5	320	4.47	JINAK	TIDAK ADA	31X28X17	75.37	123.20
6	ANDA BACHTIAR	53	P3A0	11	6.9	13.6	240	16.95	JINAK	TIDAK ADA	7X4X2	5.27	43.45
7	HASNAH	41	P2A0	14	4.7	10.7	575	8.33	JINAK	TIDAK ADA	7,5X7X5	163.30	29.23
8	NULI	28	P1A0	13	7.3	11.5	305	16.49	JINAK	TIDAK ADA	11X9X9	8.26	67.40
9	ROSMAWATI	43	P1A1	15	8.2	12.4	239	3.39	GANAS	ADA	10X15X13	>600	6102.00
10	NURYANTI	48	P3A0	11	12.9	10.7	643	5.52	JINAK	TIDAK ADA	26X21X28	95.24	143.40
11	SUMARNI	56	P2A0	11	7.12	11.9	423	30.45	GANAS	TIDAK ADA	15X15X51	42.30	378.00
12	JUMRIA	40	P0A0	12	14.7	11.4	465	14.71	GANAS	TIDAK ADA	16X11X7	42.18	5400.00
13	KARMILA	21	NONA	13	7	11.8	336	17.01	JINAK	TIDAK ADA	14X12X5	20.13	5400.00
14	SINA	29	P1A0	12	10.2	10.4	366	2.98	GANAS	ADA	7,5X 3,5X3	352.41	1800.00
15	WIDYA ANGGRENI	21	P0A0	14	4.1	12.2	230	2.43	GANAS	TIDAK ADA	30X17X5	32.06	311.13
16	NURMAUIDZOH	22	P2A0	14	6.5	14.6	323	1.54	JINAK	TIDAK ADA	17X15X12	15.10	45.30

17	ALFIANI	51	P0A0	12	13.7	12.9	604	30.28	GANAS	ADA	12X10	>600	5400.00
18	ERFINA ABAS	41	P0A0	13	6.9	11.5	276	3.86	GANAS	ADA	21X26X18	124.30	372.90
19	SYAMSIA	41	P1A0	14	14.1	13	517	5.74	JINAK	ADA	15X10	341.70	1023.00
20	ANDRIANI	45	NONA	12	7.2	11.4	450	5.25	JINAK	TIDAK ADA	8X10X15	28.90	28.90
21	FINA APRILIANI	34	P0A0	11	10.7	13.1	357	20.9	JINAK	TIDAK ADA	12X11	86.62	86.62
22	SAMSIA HAYAT	43	P2A0	13	21.1	8,9	409	6.21	JINAK	TIDAK ADA	6X4,4X5	9.30	9.30
23	SITI ARIFAH	55	P8A0	12	17.3	11.5	691	5.18	JINAK	ADA	10,4X8,3	>600	5400.00
24	NURMIN	47	P0A0	12	12.2	9.8	323	5.72	GANAS	TIDAK ADA	15X6X9	>600	5400.00
25	ROSLINA	26	P0A0	15	8.7	10.8	416	25.06	GANAS	ADA	20X13X18	>600	1800.00
26	NURFAIDAH	47	P1A0	12	13.1	9.2	611	0.98	GANAS	TIDAK ADA	18X13X10	311.13	311.13
27	SELIANA	29	P1A0	14	20.1	9.8	410	4.53	GANAS	TIDAK ADA	20X6X9	>600	1800.00
28	BALKIS	53	P2A0	15	9.2	6.8	705	6.52	GANAS	ADA	25X20X18	331.00	1553.00
29	RISMA	45	P3A0	12	9.2	12.3	358	40.97	GANAS	TIDAK ADA	25X15	92.02	276.06
30	ANITA	37	P1A0	11	14.6	13.9	265	5.28	GANAS	ADA	10X10X15	396.56	1189.68
31	YUNRI	59	P5A0	11	7.8	15	349	24.78	GANAS	ADA	18X10X18	>600	5400.00
32	MIRNA	49	P3A0	10	11.6	13.7	349	1.95	GANAS	ADA	8X10X15	225.17	675.51
33	INDO ASRA	45	P2A0	11	17.9	10.7	354	24.38	JINAK	ADA	7X4X2	>600	1800.00
34	ROSMINI	56	P1A0	12	7.7	11	456	6.46	GANAS	ADA	20,13X18	343.70	3087.00
35	SUHARYANTI	38	P3A0	12	8.8	12.8	410	7.71	GANAS	TIDAK ADA	17X19	>600	1800.00
36	TENE	61	P1A2	13	11.1	9.3	302	4.44	JINAK	ADA	20X15X12	14.47	43.41
37	ASNI HAFID	44	NONA	15	7.3	10.4	435	1.43	JINAK	TIDAK ADA	7X8X7	11.20	33.60



38	MASRITNO	54	P0A0	12	8.1	12	542	7.77	GANAS	TIDAK ADA	18X14X20	360.89	1800.00
39	NURMALA DEWI	25	P0A0	11	10	11.9	337	2.97	JINAK	TIDAK ADA	10X9	136.33	345.22
40	WAHYUNI	38	P0A0	12	4.9	11.2	323	4.43	JINAK	TIDAK ADA	15X10	18.83	56.49
41	RAHMA DAHLAN	46	P0A0	12	7.7	10.1	437	13.37	GANAS	TIDAK ADA	30X25	192.00	576.00
42	WIDIA WATI	30	P0A0	13	9.3	12.5	416	3.31	JINAK	TIDAK ADA	23X20X18	59.10	177.30
43	ST.SAHIBAH	67	P0A0	14	11	11.8	587	3.89	JINAK	TIDAK ADA	12,5X8,7X12,8	15.59	139.86
44	I JOHA	62	P4A1	13	9.3	14.3	662	1.88	GANAS	TIDAK ADA	9X10X9	106.23	956.07
45	MULYANA	38	P0A0	14	7.4	15.1	433	5.41	GANAS	TIDAK ADA	24X15X15	9.21	27.63
46	JUNIATI	23	P0A0	14	7.7	10.1	437	5.63	GANAS	TIDAK ADA	21X20	321.31	321.30
47	SURIATI	34	P6A0	13	26.4	10.7	520	18.02	GANAS	ADA	11,9X9,7X11,6	259.80	779.40
48	HJ.ISA	51	P6A0	13	8.8	10.1	631	6.74	GANAS	TIDAK ADA	22X14X22	51.57	464.13
49	SITI MIRADJ	70	P1A0	13	9	10.2	499	4.94	GANAS	ADA	12X8	224.54	2020.86
50	ROSNAWATI	37	P0A0	12	8.1	13.4	397	4.49	GANAS	TIDAK ADA	20X15X16	237.80	711.00
51	MASLIAH LEMPANG	46	P2A1	12	7.4	11.6	354	14.51	GANAS	ADA	5,6 x7,9 x 4,8	323.73	971.19
52	DAMMA	31	P0A0	12	6.7	12.8	339	5.96	GANAS	ADA	15X17X13	225.90	9255.12
53	SURIYANA	37	P0A3	11	11.6	10.8	729	4.39	GANAS	ADA	13X14X17	>600	1800.00
54	HALIMA	44	P1A0	13	7.3	9.4	318	5.73	GANAS	ADA	23X30X18	161.61	483.00
55	NURBAYA	46	P3A0	14	7.4	15.1	433	339.4	GANAS	ADA	15X1X	5439.00	16476.00
56	BASRINANG	45	P3A0	15	7	13.6	363	3.33	JINAK	ADA	8,5X 7,9X 9,04	15.23	45.69
57	HASNAWATI	57	P3A0	12	10	12.5	346	20.33	GANAS	ADA	11,46X 8X12	6.71	60.39
58	AISA APARI	60	P2A0	12	14.5	9.8	504	1.96	GANAS	ADA	30X15X16	739.40	6651.00

59	SUMRIAH	60	P3A0	12	12.1	11.5	621	11.14	GANAS	ADA	17,9X9,2X11	120.00	1080.00
60	MARGARETA	58	P3A0	13	10.4	10.4	730	0.97	GANAS	ADA	11X9X10	458.52	4126.68
61	MASLIAH LEMPANG	46	P2A1	13	10.7	9	582	1.55	GANAS	ADA	5X8X5	323.73	971.19
62	MINARWATI YUSUS	59	P0A1	14	7.1	10.5	453	4.27	GANAS	TIDAK ADA	5X6X7	116.97	350.91
63	HERLYANA GANA	48	P0A0	14	12.6	11.3	379	6.65	GANAS	ADA	19,5X24,4X26,1	26.53	236.25
64	MARIA MAGDANLENA	50	P7A0	12	10.1	11.6	285	14.56	GANAS	TIDAK ADA	30X20X26	167.26	1505.34
65	MASHARI	47	P4A1	13	11.4	8.2	345	11.09	GANAS	ADA	20X18X10	486.70	1460.10
66	JENI	35	NONA	13	6.4	9.8	157	9.83	GANAS	ADA	30x25	97.02	261.00
67	NADIA	17	NONA	12	9.7	12.3	361	2.63	JINAK	TIDAK ADA	18X21X26	54.94	54.94
68	NOVA	61	P2A0	12	8.5	8.9	487	9.52	GANAS	ADA	17,5X13,32X16,8	184.57	552.00
69	YUSNIAR	52	P4A1	12	9.6	10.1	529	1.33	JINAK	TIDAK ADA	15X11X16	9.09	27.20
70	MEIS TEMPO	50	NONA	14	5.1	10	330	5.83	JINAK	TIDAK ADA	27X15X30	5.74	5.74
71	RAHMATANG	50	P2A0	13	7.7	12.6	472	2.45	JINAK	TIDAK ADA	3X2X1	4.12	12.36
72	SITA SIPI	54	P6A1	13	8.2	15.1	642	2.05	GANAS	ADA	14X12X13	143.51	1291.59
73	PANCA	25	P0A0	12	7.4	8.4	470	3.67	GANAS	TIDAK ADA	22X21X18	31.53	428.74
74	IDAYANTI ARSAD	51	P0A0	12	8.1	9.3	492	7.09	JINAK	TIDAK ADA	9X5X1X5	5.05	0.63
75	BASMIATI	51	NONA	13	11.4	9.1	332	18.03	GANAS	TIDAK ADA	29X29X10	108.73	972.00
76	SITI ROHYATI	32	P1A0	13	12.6	10.4	521	6.73	GANAS	TIDAK ADA	9X100X13	234.30	234.30
77	NUHURIA TUMODO	65	P0A0	14	8.9	11.1	789	4.25	GANAS	ADA	13X11X11	>600	5400.00
78	AGUSITA P	51	P1A0	12	11.4	12.3	445	13.4	GANAS	TIDAK ADA	16X9X13	67.37	202.11

79	LULU	29	P1A0	13	6.4	11.9	517	6.33	GANAS	TIDAK ADA	14X15X24	267.58	802.74
80	MULIANA	28	P1A0	14	12.7	9.8	351	5.8	JINAK	TIDAK ADA	20X20	2.36	2.36
81	NURTINAH	51	P0A0	12	8.5	13.8	487	6.99	GANAS	ADA	10X9X12	>600	5400.00

**LAMPIRAN 7.**

**HASIL OLAH DATA**

**Descriptive Statistics**

	N	Minimum	Maximum	Mean	Std. Deviation
Umur1	81	17.00	70.00	43.7901	12.93514
Leukosit1	81	2.30	26.40	9.8941	3.84691
HB1	81	6.80	89.00	12.4099	8.78995
Trombosit1	81	157.00	789.00	439.3086	137.50915
IL61	81	.97	339.40	12.4879	37.59146
Valid N (listwise)	81				

**Usia**

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid < 60	72	88.9	88.9	88.9
≥6	9	11.1	11.1	100.0
Total	81	100.0	100.0	

**Paritas**

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Nulipara	33	40.7	40.7	40.7
Primi/multi/grandmulti para	48	59.3	59.3	100.0
Total	81	100.0	100.0	

**Usia menarke**

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid < 12	10	12.3	12.3	12.3
≥12	71	87.7	87.7	100.0
Total	81	100.0	100.0	

**Leukosit**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Leukositosis	26	32.1	32.1	32.1
	Normal	55	67.9	67.9	100.0
	Total	81	100.0	100.0	

**HB**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Anemia	53	65.4	65.4	65.4
	Normal	28	34.6	34.6	100.0
	Total	81	100.0	100.0	

**Trombosit**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Normal	35	43.2	43.2	43.2
	Trombositosis	46	56.8	56.8	100.0
	Total	81	100.0	100.0	

**Asites**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ADA	36	44.4	44.4	44.4
	TIDAK ADA	45	55.6	55.6	100.0
	Total	81	100.0	100.0	

**Perlengketan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ADA	54	66.7	66.7	66.7
	TIDAK ADA	27	33.3	33.3	100.0
	Total	81	100.0	100.0	

**Ukuran\_tumor**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 10	12	14.8	14.8	14.8
	≥10	69	85.2	85.2	100.0
	Total	81	100.0	100.0	

**Nyeri\_tekan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ADA	17	21.0	21.0	21.0
	TIDAK ADA	64	79.0	79.0	100.0
	Total	81	100.0	100.0	

**Edema**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ADA	12	14.8	14.8	14.8
	TIDAK ADA	69	85.2	85.2	100.0
	Total	81	100.0	100.0	

**IL6**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 3.75	22	27.2	27.2	27.2
	≥3.7	59	72.8	72.8	100.0
	Total	81	100.0	100.0	

**CA\_125**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 35	22	27.2	27.2	27.2
	≥ 35	59	72.8	72.8	100.0
	Total	81	100.0	100.0	

**RMI**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 200	22	27.2	27.2	27.2
	≥ 200	59	72.8	72.8	100.0
	Total	81	100.0	100.0	

**Keganasan**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	GANAS	54	66.7	66.7	66.7
	JINAK	27	33.3	33.3	100.0
	Total	81	100.0	100.0	

```

CROSSTABS
  /TABLES=Usia Paritas Usia menarke Leukosit HB Trombosit Asites
  Perlengketan Ukuran_tumor IL6 BY
  Keganasan
  /FORMAT=AVALUE TABLES
  /STATISTICS=CHISQ RISK
  /CELLS=COUNT ROW COLUMN TOTAL
  /COUNT ROUND CELL.

```

## Crosstabs

### Usia \* Keganasan

**Crosstab**

		Keganasan		Total	
		GANAS	JINAK		
Usia	< 60	Count	48	24	72
		% within Usia	66.7%	33.3%	100.0%
		% within Keganasan	88.9%	88.9%	88.9%
		% of Total	59.3%	29.6%	88.9%
≥6		Count	6	3	9
		% within Usia	66.7%	33.3%	100.0%
		% within Keganasan	11.1%	11.1%	11.1%
		% of Total	7.4%	3.7%	11.1%
Total		Count	54	27	81
		% within Usia	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%
		% of Total	66.7%	33.3%	100.0%



**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.000 <sup>a</sup>	1	1.000		
Continuity Correction <sup>b</sup>	.000	1	1.000		
Likelihood Ratio	.000	1	1.000		
Fisher's Exact Test				1.000	.656
N of Valid Cases	81				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.00.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Usia (< 60 / ≥6)	1.000	.230	4.349
For cohort Keganasan = GANAS	1.000	.613	1.632
For cohort Keganasan = JINAK	1.000	.375	2.664
N of Valid Cases	81		

**Paritas \* Keganasan**

**Crosstab**

			Keganasan		Total
			GANAS	JINAK	
Paritas	Nulipara	Count	21	12	33
		% within Paritas	63.6%	36.4%	100.0%
		% within Keganasan	38.9%	44.4%	40.7%
		% of Total	25.9%	14.8%	40.7%
Primi/multi/grandmulti para		Count	33	15	48
		% within Paritas	68.8%	31.3%	100.0%
		% within Keganasan	61.1%	55.6%	59.3%
		% of Total	40.7%	18.5%	59.3%
Total		Count	54	27	81
		% within Paritas	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%

% of Total	66.7%	33.3%	100.0%
------------	-------	-------	--------

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.230 <sup>a</sup>	1	.631		
Continuity Correction <sup>b</sup>	.058	1	.810		
Likelihood Ratio	.229	1	.632		
Fisher's Exact Test				.640	.404
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.00.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Paritas (Nulipara / Primi/multi/grandmulti para)	.795	.312	2.028
For cohort Keganasan = GANAS	.926	.672	1.276
For cohort Keganasan = JINAK	1.164	.628	2.155
N of Valid Cases	81		

### Usia\_menarke \* Keganasan

#### Crosstab

			Keganasan		Total
			GANAS	JINAK	
Usia_menarke < 12	Count		5	5	10
	% within Usia_menarke		50.0%	50.0%	100.0%
	% within Keganasan		9.3%	18.5%	12.3%
	% of Total		6.2%	6.2%	12.3%
≥1	Count		49	22	71

	% within Usia_menarke	69.0%	31.0%	100.0%
	% within Keganasan	90.7%	81.5%	87.7%
	% of Total	60.5%	27.2%	87.7%
Total	Count	54	27	81
	% within Usia_menarke	66.7%	33.3%	100.0%
	% within Keganasan	100.0%	100.0%	100.0%
	% of Total	66.7%	33.3%	100.0%

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.426 <sup>a</sup>	1	.232		
Continuity Correction <sup>b</sup>	.699	1	.403		
Likelihood Ratio	1.356	1	.244		
Fisher's Exact Test				.288	.199
N of Valid Cases	81				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.33.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Usia_menarke (< 12 / ≥1)	.449	.118	1.711
For cohort Keganasan = GANAS	.724	.382	1.373
For cohort Keganasan = JINAK	1.614	.793	3.283
N of Valid Cases	81		

## Leukosit \* Keganasan

Crosstab

			Keganasan		Total
			GANAS	JINAK	
Leukosit	Leukositosis	Count	18	8	26
		% within Leukosit	69.2%	30.8%	100.0%
		% within Keganasan	33.3%	29.6%	32.1%
		% of Total	22.2%	9.9%	32.1%
	Normal	Count	36	19	55
		% within Leukosit	65.5%	34.5%	100.0%
		% within Keganasan	66.7%	70.4%	67.9%
		% of Total	44.4%	23.5%	67.9%
Total		Count	54	27	81
		% within Leukosit	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%
		% of Total	66.7%	33.3%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.113 <sup>a</sup>	1	.736		
Continuity Correction <sup>b</sup>	.007	1	.933		
Likelihood Ratio	.114	1	.736		
Fisher's Exact Test				.805	.471
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 8.67.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Leukosit (Leukositosis / Normal)	1.188	.436	3.232
For cohort Keganasan = GANAS	1.058	.768	1.457
For cohort Keganasan = JINAK	.891	.450	1.761
N of Valid Cases	81		

**HB \* Keganasan**

**Crosstab**

			Keganasan		Total
			GANAS	JINAK	
HB	Anemia	Count	36	17	53
		% within HB	67.9%	32.1%	100.0%
		% within Keganasan	66.7%	63.0%	65.4%
		% of Total	44.4%	21.0%	65.4%
	Normal	Count	18	10	28
		% within HB	64.3%	35.7%	100.0%
		% within Keganasan	33.3%	37.0%	34.6%
		% of Total	22.2%	12.3%	34.6%
Total	Count	54	27	81	
	% within HB	66.7%	33.3%	100.0%	
	% within Keganasan	100.0%	100.0%	100.0%	
	% of Total	66.7%	33.3%	100.0%	

### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.109 <sup>a</sup>	1	.741		
Continuity Correction <sup>b</sup>	.007	1	.934		
Likelihood Ratio	.109	1	.742		
Fisher's Exact Test				.806	.464
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.33.

b. Computed only for a 2x2 table

### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for HB (Anemia / Normal)	1.176	.448	3.086
For cohort Keganasan = GANAS	1.057	.758	1.473
For cohort Keganasan = JINAK	.898	.477	1.691
N of Valid Cases	81		

### Trombosit \* Keganasan

#### Crosstab

			Keganasan		Total
			GANAS	JINAK	
Trombosit	Normal	Count	21	14	35
		% within Trombosit	60.0%	40.0%	100.0%
		% within Keganasan	38.9%	51.9%	43.2%
		% of Total	25.9%	17.3%	43.2%
Trombositosis		Count	33	13	46
		% within Trombosit	71.7%	28.3%	100.0%
		% within Keganasan	61.1%	48.1%	56.8%
		% of Total	40.7%	16.0%	56.8%

Total	Count	54	27	81
	% within Trombosit	66.7%	33.3%	100.0%
	% within Keganasan	100.0%	100.0%	100.0%
	% of Total	66.7%	33.3%	100.0%

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.233 <sup>a</sup>	1	.267		
Continuity Correction <sup>b</sup>	.761	1	.383		
Likelihood Ratio	1.228	1	.268		
Fisher's Exact Test				.343	.191
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.67.

b. Computed only for a 2x2 table.

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Trombosit (Normal / Trombositosis)	.591	.233	1.501
For cohort Keganasan = GANAS	.836	.604	1.158
For cohort Keganasan = JINAK	1.415	.766	2.615
N of Valid Cases	81		

#### Asites \* Keganasan

#### Crosstab

			Keganasan		Total
			GANAS	JINAK	
Asites	ADA	Count	31	5	36
		% within Asites	86.1%	13.9%	100.0%

	% within Keganasan	57.4%	18.5%	44.4%
	% of Total	38.3%	6.2%	44.4%
TIDAK ADA	Count	23	22	45
	% within Asites	51.1%	48.9%	100.0%
	% within Keganasan	42.6%	81.5%	55.6%
	% of Total	28.4%	27.2%	55.6%
Total	Count	54	27	81
	% within Asites	66.7%	33.3%	100.0%
	% within Keganasan	100.0%	100.0%	100.0%
	% of Total	66.7%	33.3%	100.0%

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	11.025 <sup>a</sup>	1	.001		
Continuity Correction <sup>b</sup>	9.506	1	.002		
Likelihood Ratio	11.742	1	.001		
Fisher's Exact Test				.001	.001
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.00.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Asites (ADA / TIDAK ADA)	5.930	1.953	18.009
For cohort Keganasan = GANAS	1.685	1.230	2.307
For cohort Keganasan = JINAK	.284	.119	.676
N of Valid Cases	81		



## Perlengketan \* Keganasan

Crosstab

			Keganasan		Total
			GANAS	JINAK	
Perlengketan	ADA	Count	38	16	54
		% within Perlengketan	70.4%	29.6%	100.0%
		% within Keganasan	70.4%	59.3%	66.7%
		% of Total	46.9%	19.8%	66.7%
	TIDAK ADA	Count	16	11	27
		% within Perlengketan	59.3%	40.7%	100.0%
		% within Keganasan	29.6%	40.7%	33.3%
		% of Total	19.8%	13.6%	33.3%
Total	Count	54	27	81	
	% within Perlengketan	66.7%	33.3%	100.0%	
	% within Keganasan	100.0%	100.0%	100.0%	
	% of Total	66.7%	33.3%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.000 <sup>a</sup>	1	.317		
Continuity Correction <sup>b</sup>	.563	1	.453		
Likelihood Ratio	.986	1	.321		
Fisher's Exact Test				.330	.226
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.00.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perlengketan (ADA / TIDAK ADA)	1.633	.622	4.284
For cohort Keganasan = GANAS	1.188	.831	1.698
For cohort Keganasan = JINAK	.727	.394	1.343
N of Valid Cases	81		

**Ukuran\_tumor \* Keganasan**

**Crosstab**

			Keganasan		Total
			GANAS	JINAK	
Ukuran_tumor	< 10	Count	4	8	12
		% within Ukuran_tumor	33.3%	66.7%	100.0%
		% within Keganasan	7.4%	29.6%	14.8%
		% of Total	4.9%	9.9%	14.8%
Ukuran_tumor	≥10	Count	50	19	69
		% within Ukuran_tumor	72.5%	27.5%	100.0%
		% within Keganasan	92.6%	70.4%	85.2%
		% of Total	61.7%	23.5%	85.2%
Total		Count	54	27	81
		% within Ukuran_tumor	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%
		% of Total	66.7%	33.3%	100.0%

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	7.043 <sup>a</sup>	1	.008		

Continuity Correction <sup>b</sup>	5.393	1	.020		
Likelihood Ratio	6.623	1	.010		
Fisher's Exact Test				.017	.012
N of Valid Cases	81				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.00.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Ukuran_tumor (< 10 / ≥10)	.190	.051	.705
For cohort Keganasan = GANAS	.460	.204	1.037
For cohort Keganasan = JINAK	2.421	1.392	4.212
N of Valid Cases	81		

#### IL6 \* Keganasan

##### Crosstab

			Keganasan		Total
			GANAS	JINAK	
IL6	< 3.75	Count	13	9	22
		% within IL6	59.1%	40.9%	100.0%
		% within Keganasan	24.1%	33.3%	27.2%
		% of Total	16.0%	11.1%	27.2%
	≥3.7	Count	41	18	59
		% within IL6	69.5%	30.5%	100.0%
		% within Keganasan	75.9%	66.7%	72.8%
		% of Total	50.6%	22.2%	72.8%
Total		Count	54	27	81
		% within IL6	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%

% of Total	66.7%	33.3%	100.0%
------------	-------	-------	--------

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.780 <sup>a</sup>	1	.377		
Continuity Correction <sup>b</sup>	.382	1	.536		
Likelihood Ratio	.765	1	.382		
Fisher's Exact Test				.432	.266
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.33.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for IL6 (< 3.75 / ≥3.7)	.634	.230	1.749
For cohort Keganasan = GANAS	.850	.578	1.252
For cohort Keganasan = JINAK	1.341	.712	2.525
N of Valid Cases	81		

#### Crosstab

			Keganasan		Total
			GANAS	JINAK	
Nyeri_tekan	ADA	Count	12	5	17
		% within Nyeri_tekan	70.6%	29.4%	100.0%
		% within Keganasan	22.2%	18.5%	21.0%
		% of Total	14.8%	6.2%	21.0%
	TIDAK ADA	Count	42	22	64
		% within Nyeri_tekan	65.6%	34.4%	100.0%
		% within Keganasan	77.8%	81.5%	79.0%
		% of Total	51.9%	27.2%	79.0%

Total	Count	54	27	81
	% within Nyeri_tekan	66.7%	33.3%	100.0%
	% within Keganasan	100.0%	100.0%	100.0%
	% of Total	66.7%	33.3%	100.0%

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.149 <sup>a</sup>	1	.700		
Continuity Correction <sup>b</sup>	.009	1	.923		
Likelihood Ratio	.151	1	.697		
Fisher's Exact Test				.779	.469
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.67.

b. Computed only for a 2x2 table.

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Nyeri_tekan (ADA / TIDAK ADA)	1.257	.393	4.026
For cohort Keganasan = GANAS	1.076	.755	1.533
For cohort Keganasan = JINAK	.856	.380	1.924
N of Valid Cases	81		

#### Crosstab

	Keganasan		Total
	GANAS	JINAK	

Edema	ADA	Count	10	2	12
		% within Edema	83.3%	16.7%	100.0%
		% within Keganasan	18.5%	7.4%	14.8%
		% of Total	12.3%	2.5%	14.8%
TIDAK ADA		Count	44	25	69
		% within Edema	63.8%	36.2%	100.0%
		% within Keganasan	81.5%	92.6%	85.2%
		% of Total	54.3%	30.9%	85.2%
Total		Count	54	27	81
		% within Edema	66.7%	33.3%	100.0%
		% within Keganasan	100.0%	100.0%	100.0%
		% of Total	66.7%	33.3%	100.0%

#### Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.761 <sup>a</sup>	1	.185		
Continuity Correction <sup>b</sup>	.990	1	.320		
Likelihood Ratio	1.948	1	.163		
Fisher's Exact Test				.320	.160
N of Valid Cases	81				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.00.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Edema (ADA / TIDAK ADA)	2.841	.576	14.009
For cohort Keganasan = GANAS	1.307	.959	1.780

For cohort Keganasan =	.460	.125	1.693
JINAK			
N of Valid Cases	81		

**Crosstab**

			Keganasan		Total
			GANAS	JINAK	
CA_125 < 35	Count	5	17	22	
	% within CA_125	22.7%	77.3%	100.0%	
	% within Keganasan	9.3%	63.0%	27.2%	
	% of Total	6.2%	21.0%	27.2%	
CA_125 ≥ 35	Count	49	10	59	
	% within CA_125	83.1%	16.9%	100.0%	
	% within Keganasan	90.7%	37.0%	72.8%	
	% of Total	60.5%	12.3%	72.8%	
Total	Count	54	27	81	
	% within CA_125	66.7%	33.3%	100.0%	
	% within Keganasan	100.0%	100.0%	100.0%	
	% of Total	66.7%	33.3%	100.0%	

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	26.241 <sup>a</sup>	1	.000		
Continuity Correction <sup>b</sup>	23.596	1	.000		
Likelihood Ratio	25.834	1	.000		
Fisher's Exact Test				.000	.000
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.33.

b. Computed only for a 2x2 table.

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for CA_125 (< 35 / ≥ 35)	.060	.018	.201
For cohort Keganasan = GANAS	.274	.126	.596
For cohort Keganasan = JINAK	4.559	2.481	8.379
N of Valid Cases	81		

**Crosstab**

			Keganasan		Total
			GANAS	JINAK	
RMI < 200	Count	2	20	22	
	% within RMI	9.1%	90.9%	100.0%	
	% within Keganasan	3.7%	74.1%	27.2%	
	% of Total	2.5%	24.7%	27.2%	
RMI ≥ 200	Count	52	7	59	
	% within RMI	88.1%	11.9%	100.0%	
	% within Keganasan	96.3%	25.9%	72.8%	
	% of Total	64.2%	8.6%	72.8%	
Total	Count	54	27	81	
	% within RMI	66.7%	33.3%	100.0%	
	% within Keganasan	100.0%	100.0%	100.0%	
	% of Total	66.7%	33.3%	100.0%	



### Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	45.055 <sup>a</sup>	1	.000		
Continuity Correction <sup>b</sup>	41.569	1	.000		
Likelihood Ratio	46.734	1	.000		
Fisher's Exact Test				.000	.000
N of Valid Cases	81				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.33.

b. Computed only for a 2x2 table

### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for RMI (< 200 / ≥ 200)	.013	.003	.070
For cohort Keganasan = GANAS	.103	.027	.388
For cohort Keganasan = JINAK	7.662	3.775	15.553
N of Valid Cases	81		

**LAMPIRAN 8.**

**HASIL DATA PENELITIAN**

